European Independent Consultant on Cancer Clinical Development Program
10-2016 - AhoraServicios personales • Led and developed of Phase I, II and III clinical trials for different molecules and tumors (brigatinib for lung cancer [NSCLC ALK+]; olaparib for endometrial cancer; osimertinib for NSCLC + EGFR T790M; Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer; ruxolitinib versus best available therapy in patients with Polycythemia Vera who are hydroxyurea resistant or intolerant; ruxolitinib for patients with primary myelofibrosis (PMF) or post-polycythemia vera myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF)).
• Maintain bilateral communication and solid professional relationships between site PIs, investigator teams, KOLs and Pharmaceutical’s medical department to support the medical/scientific information and research needs.
• Develop and conduct training sessions on scientific/medical information at specific training events and site initiation visits.